Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Pralsetinib |
Trade Name | Gavreto |
Synonyms | BLU667|BLU-667 |
Drug Descriptions |
Gavreto (pralsetinib) is a small molecule inhibitor that selectively targets activated Ret, which may result in antitumor activity including inhibition of tumor growth and tumor regression (PMID: 29657135). Gavreto (pralsetinib) is FDA approved for use in patients with metastatic RET fusion-positive non-small cell lung cancer, in adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer, and in adult and pediatric patients 12 years of age and older with RET fusion-positive thyroid cancer who are radioactive iodine-refractory (FDA.gov). |
DrugClasses | RET Inhibitor 52 |
CAS Registry Number | 2097132-94-8 |
NCIT ID | C132295 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Afatinib + Pralsetinib | Afatinib Pralsetinib | 0 | 0 |
Crizotinib + Pralsetinib | Crizotinib Pralsetinib | 0 | 0 |
Ensartinib + Pralsetinib | Ensartinib Pralsetinib | 0 | 0 |
JC-010a + Pralsetinib | JC-010a Pralsetinib | 0 | 0 |
Osimertinib + Pralsetinib | Osimertinib Pralsetinib | 0 | 0 |
Palbociclib + Pralsetinib | Palbociclib Pralsetinib | 0 | 0 |
Pralsetinib | Pralsetinib | 52 | 5 |